Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Overview
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmahungary Group
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Drug Profiles
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
Apr 16, 2019: Paradigm’s knee osteoarthritis study meets secondary endpoints
Feb 14, 2019: Paradigm’s orphan phase 2/3 clinical program progresses
Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction
Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction
Aug 28, 2018: Paradigm’s phase 2 a Ross River virus clinical trial recruitment filised
Aug 15, 2018: Paradigm achieves 60% reduction in osteoarthritis pain
Aug 06, 2018: Paradigm achieves 100% recruitment in Phase 2b Osteoarthritis Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aquilus Pharmaceuticals Inc, H1 2020
Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Pharmahungary Group, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020